Evidence map›Paper›PMID 31797450›Full record

ArticleJournal of clinical laboratory analysis2020

Pre-miR-27a rs895819 polymorphism and risk of diffuse large B-cell lymphoma.

Weiyan Tang, Haonan Xu, Dawei Ma, Rong Ma, Jianqiu Wu, Xinnian Yu, Jifeng Feng, Qizhan Liu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Association between HOTAIR Polymorphisms and Lymphoma.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Weiyan TangThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.ORCID https://orcid.org/0000-0002-1401-0512
Haonan XuSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Dawei MaThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Rong MaThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Jianqiu WuThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Xinnian YuThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Jifeng FengThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Qizhan LiuJiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer, Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
Jiangsu Cancer Hospital · CNChina Pharmaceutical University · CNNanjing Medical University · CN

Funding

Jiangsu Provincial Commission of Health and Family Planning H201511Jiangsu Provincial Key Research Development Program BE2016794Nanjing Science and Technology Project 2017sc512032open Project of Jiangsu Collaborative Innovation Center for Cancer, Personalized Medicine JX21817902/009
6 · The paper itself

Abstract

backgroundRecently, several studies have investigated the relationship between Pre-miR-27a rs895819 polymorphism and risk of various cancers. However, the relationship between rs895819 and diffuse large B-cell lymphoma (DLBCL) has not been well known.

methodsIn this study, we conducted a case-control study to explore the role of Pre-miR-27a rs895819 in risk of DLBCL. The PCR-TaqMan and luciferase assays and in vitro experiments were used to evaluate polymorphism function.

resultsAs a result, we found subjects carrying with rs895819 AG/GG genotype had a significantly decreased risk when compared with those carrying the AA genotype. Further qPCR assay showed that the DLBCL patients carrying AG/GG genotypes showed a lower level of mature miR-27a when compared with patients carrying AA genotype. Moreover, miR-27a levels were upregulated in DLBCL tissues compared with normal lymphoid tissues. Further in vitro experiments showed that miR-27a might function as an oncogene through target TGFBR1. In addition, TGFBR1 overexpression rescues effects of miR-27a inhibitor on DLBCL cells phenotypes.

conclusionsIn conclusion, these findings indicate that rs895819 A > G might reduce the expression of mature miR-27a, and leading a higher level of TGFBR1, ultimately inhibiting the development of DLBCL.

Indexed as

Genetic Predisposition to DiseaseBase SequenceCase-Control StudiesCell Line, TumorFemaleGene Expression Regulation, NeoplasticGenetic Association StudiesHumansLymphoma, Large B-Cell, DiffuseMaleMicroRNAsMiddle AgedPhenotypePolymorphism, Single NucleotideReceptor, Transforming Growth Factor-beta Type IRisk AssessmentMicroRNAsMIRN27 microRNA, humanReceptor, Transforming Growth Factor-beta Type IRNA PrecursorsTGFBR1 protein, humanDLBCLPre-miR-27aSNPTGFBR1

Identifiers

PMID31797450
PMCPMC7083450
OpenAlexW2993991705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.